The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The PedAL master trial and sub-studies: accelerating drug development in pediatric acute leukemias
In this interview, Gwen Nichols, MD, Blood Cancer United, Washington, DC, provides insight into the Pediatric Acute Leukemia (PedAL) master trial (NCT04726241) and sub-studies, which aim to accelerate pediatric drug development in acute leukemias to address the need for a greater number of effective treatment options in this patient population. Dr Nichols highlights that the screening trial has enabled over 500 pediatric patients to receive free molecular sequencing, and two sub-trials are currently underway: a large international randomized trial of standard relapse therapy with or without venetoclax, and a trial investigating the menin inhibitor ziftomenib. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
